5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors. They support companies solving important healthcare needs via cutting-edge breakthroughs in medicine and science. Their portfolio companies spearhead novel approaches to diagnose, prevent and treat a wide range of medical conditions.
5AM’s investment professionals possess strong scientific, medical, operational, legal and finance expertise. Their complementary backgrounds provide them with a unique edge to find and shape life science portfolio companies. Their team employs a time-tested, hands-on approach to company building and, in addition to being an early investor and contributing as board members, 5AM is often directly involved in setting company strategy, management recruiting, business development and fundraising, and they frequently take on short-term operating roles.
Clarus Ventures is a global investment firm dedicated to life sciences. Founded in 2005 by a team of accomplished investment and operating professionals, they approach healthcare investing with a passion for novel ideas and the discipline to generate attractive and predictable returns. Clarus manages $1.7 billion of assets across three funds. Through multiple platforms they have invested in over 50 private and public companies in the biotechnology, medical device, and diagnostic spaces.
Clarus Ventures’ expertise has enabled them to establish a long history of creating value through partnerships with entrepreneurs, the biopharmaceutical and medical technology industries to develop cutting edge therapeutics, devices, and diagnostics. Their diverse network has allowed them to source and capitalize on unique investment opportunities.
In every investment Clarus employs a hands-on philosophy and adhere to their investment principals which are founded on their core competencies of development and clinical expertise, regulatory knowledge, and the ability to adapt to an ever changing investment landscape. Clarus strives to generate outstanding returns for their investors and thrive on discovering and developing innovative products that improve people’s lives.
New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $17 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions since its founding in 1977. In the U.S., NEA has offices in Menlo Park, CA; Boston, MA; New York, NY; Chicago, IL; and the Washington, D.C. metropolitan area. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China. For additional information, visit www.nea.com.
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with approximately $15 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team manages a series of private equity funds, public equity funds, royalty/debt funds, and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.
USVP is a leading venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the past thirty-plus years of the firm's existence. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals and industry domain experts.
Nextech Invest Ltd
The global oncology specialist private equity firm Nextech Invest Ltd., established in 1998 in Zurich, Switzerland, focuses on investing in cancer companies. Supported by a Scientific Board of eight oncologists chaired by Prof. Dr. David Livingston, Deputy Director of Dana-Farber/Harvard Cancer Center, Nextech Invest invests in emerging companies with pioneering innovations in cancer that have compounds entering clinical trials. The other members of the Scientific Board include: Prof. Dr. Karl- Heinz Altmann, Prof. Dr. Philip Greenberg, Prof. Dr. William Kaelin, Dr. Charles Sawyers, Prof. Dr. Paul Workman, Dr. Kai Wucherpfennig and distinguished scientific advisor Prof. Dr. Sir Bruce Ponder. Nextech Invest is a longstanding member of SECA, and works closely with the Union for International Cancer Control (UICC).
Astellas Venture Management
Astellas Venture Management LLC (AVM), located in Menlo Park California, is the pure strategic corporate venture capital arm of Astellas Pharma Inc., a global pharmaceutical company headquartered in Japan. They are investing in early preclinical stage companies, especially emerging biotechnology companies dedicated to development of new therapeutics and new drug discovery platform technology. The venture capital activity of AVM can trace back to Astellas Venture Capital LLC, originally founded as Yamanouchi Venture Capital LLC in 2000 and Fujisawa Investments for Entrepreneurship LP established in 1999.
Osage University Partners
Osage University Partners (OUP) is a venture capital fund that partners with leading innovative universities and research institutions to invest in their spinouts via the exercise of participation rights. OUP currently has over 80 institutional partners and has invested in over 55 companies that have spun out of those institutions. The firm is currently investing its second fund, raised in 2015.
Arcus Ventures is a venture capital firm specializing in investments in oncology focused companies. The firm invests in oncology companies with biopharmaceuticals and/or new drug delivery platforms in development, device companies with products that have pre-marketing approval, companies dedicated to cancer treatment, and service companies with positive revenue (therapeutics, device, diagnostics, services). It aims to invest in companies which make innovative products based on proprietary technology and design. Arcus Ventures was founded in 2007 and is based in New York City.